Merck Price to Sales Ratio 2010-2024 | MRK

Historical PS ratio values for Merck (MRK) over the last 10 years. The current P/S ratio for Merck as of February 10, 2025 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merck P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2025-02-07 87.28 3.51
2024-09-30 112.65 $24.83 4.54
2024-06-30 122.01 $24.55 4.97
2024-03-31 129.26 $24.14 5.36
2023-12-31 106.12 $23.61 4.49
2023-09-30 99.49 $23.31 4.27
2023-06-30 110.76 $22.93 4.83
2023-03-31 101.44 $22.75 4.46
2022-12-31 105.07 $23.34 4.50
2022-09-30 81.03 $23.23 3.49
2022-06-30 85.10 $22.53 3.78
2022-03-31 75.97 $21.27 3.57
2021-12-31 70.34 $19.19 3.67
2021-09-30 68.29 $17.47 3.91
2021-06-30 70.08 $16.59 4.22
2021-03-31 68.87 $15.79 4.36
2020-12-31 72.45 $16.34 4.43
2020-09-30 72.88 $14.34 5.08
2020-06-30 67.45 $14.85 4.54
2020-03-31 66.58 $15.71 4.24
2019-12-31 78.08 $15.13 5.16
2019-09-30 71.78 $17.62 4.07
2019-06-30 71.03 $16.84 4.22
2019-03-31 69.99 $16.17 4.33
2018-12-31 63.87 $15.72 4.06
2018-09-30 58.87 $15.41 3.82
2018-06-30 50.03 $15.17 3.30
2018-03-31 44.55 $14.89 2.99
2017-12-31 45.62 $14.60 3.12
2017-09-30 51.47 $14.43 3.57
2017-06-30 51.16 $14.43 3.55
2017-03-31 50.34 $14.35 3.51
2016-12-31 46.30 $14.27 3.24
2016-09-30 48.72 $14.24 3.42
2016-06-30 44.64 $14.01 3.19
2016-03-31 40.66 $13.91 2.92
2015-12-31 40.25 $13.87 2.90
2015-09-30 37.30 $13.85 2.69
2015-06-30 42.63 $13.93 3.06
2015-03-31 42.72 $14.20 3.01
2014-12-31 41.87 $14.37 2.91
2014-09-30 43.37 $14.57 2.98
2014-06-30 42.02 $14.67 2.86
2014-03-31 40.93 $14.62 2.80
2013-12-31 35.80 $14.66 2.44
2013-09-30 33.75 $14.70 2.30
2013-06-30 32.63 $14.70 2.22
2013-03-31 30.77 $15.05 2.04
2012-12-31 28.23 $15.37 1.84
2012-09-30 30.80 $15.53 1.98
2012-06-30 28.25 $15.69 1.80
2012-03-31 25.70 $15.59 1.65
2011-12-31 24.96 $15.50 1.61
2011-09-30 21.39 $15.40 1.39
2011-06-30 22.81 $15.10 1.51
2011-03-31 21.11 $14.82 1.42
2010-12-31 22.78 $14.73 1.55
2010-09-30 23.03 $15.29 1.51
2010-06-30 21.65 $14.57 1.49
2010-03-31 22.87 $13.74 1.67
2009-12-31 22.15 $12.65 1.75
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $222.734B $64.168B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $826.256B 66.95
Novo Nordisk (NVO) Denmark $391.178B 26.50
Johnson & Johnson (JNJ) United States $369.594B 15.37
AbbVie (ABBV) United States $341.005B 19.07
Roche Holding AG (RHHBY) Switzerland $252.630B 0.00
AstraZeneca (AZN) United Kingdom $224.395B 17.61
Novartis AG (NVS) Switzerland $218.667B 13.70
Pfizer (PFE) United States $146.378B 8.31
Sanofi (SNY) $134.176B 12.71
Bayer (BAYRY) Germany $21.810B 3.49
Innoviva (INVA) United States $1.143B 9.51